The Patent Finder

Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib

Sanofi-Aventis

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,533,411Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib
In force
 · High confidence
Sanofi-Aventis U.S. LLCIn forceHigh confidence
Application 19/417,983Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib
Pending
Not granted
Sanofi-Aventis U.S. LLCPendingNot granted
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Sanofi-Aventis.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited